|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-9-27
|
|
pubmed:abstractText |
Metformin is considered contraindicated in patients with heart failure because of concerns over lactic acidosis, despite increasing evidence of potential benefit. The aim of this study was to evaluate the association between metformin and clinical outcomes in patients with heart failure and type 2 diabetes.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0149-5992
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2345-51
|
|
pubmed:dateRevised |
2008-2-8
|
|
pubmed:meshHeading |
pubmed-meshheading:16186261-Aged,
pubmed-meshheading:16186261-Aged, 80 and over,
pubmed-meshheading:16186261-Cohort Studies,
pubmed-meshheading:16186261-Databases, Factual,
pubmed-meshheading:16186261-Diabetes Mellitus, Type 2,
pubmed-meshheading:16186261-Female,
pubmed-meshheading:16186261-Heart Failure,
pubmed-meshheading:16186261-Hospitalization,
pubmed-meshheading:16186261-Humans,
pubmed-meshheading:16186261-Hypoglycemic Agents,
pubmed-meshheading:16186261-Male,
pubmed-meshheading:16186261-Metformin,
pubmed-meshheading:16186261-Middle Aged,
pubmed-meshheading:16186261-Morbidity,
pubmed-meshheading:16186261-Saskatchewan,
pubmed-meshheading:16186261-Survival Analysis,
pubmed-meshheading:16186261-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Improved clinical outcomes associated with metformin in patients with diabetes and heart failure.
|
|
pubmed:affiliation |
Institute of Health Economics, Edmonton, Alberta, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
